The 2026 probiotic and secretome paper reports no trial results yet because it is a published trial protocol, not a results paper. It lays out planned methods for oral probiotics plus topical secretome in acne vulgaris.
A protocol means the treatment plan, patient groups, and measurements come first. Here, probiotics means live beneficial bacteria taken by mouth, and secretome means cell-released material applied to skin. Results can only follow enrollment, treatment, follow-up, and analysis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 2026 paper actually published
- Who will be studied and how
- Which products and outcomes the trial defines
- What acne-prone skin can do now
What the 2026 paper actually published
BMJ Open published the paper on June 4, 2026 as a protocol describing future trial methods. The paper does not contain outcome data, lesion counts, or safety results.
That design-first order is normal for clinical research. As described in the BMJ Open protocol, BMJ Open presents the intervention plan, eligibility rules, outcomes, and analysis plan before patients complete treatment.
Who will be studied and how
The protocol plans a phase 2 double-blind randomized trial in 64 patients with mild-to-moderate acne vulgaris. Patients will enter four parallel groups for direct comparison. Neither patients nor study staff will know who receives active or placebo treatment during the trial. According to the PubMed trial record, the U.S.
National Library of Medicine lists the same June 4, 2026 protocol and 64-patient, four-group design. The four arms test standard acne therapy plus oral probiotics and topical secretome, each agent alone, or dual placebo. Efficacy cannot be judged until treatment and follow-up finish. This structure separates each added effect. It also prevents early before-and-after stories from being mistaken for proof.
Which products and outcomes the trial defines
The tested oral product is HEXBIO granules with six Lactobacillus and Bifidobacterium strains. The strains include L. acidophilus BCMC 12130 and B. longum BCMC 02120. The topical partner is a secretome preparation for acne-prone skin.
Together, the pair tests a microbiome-directed idea from inside and outside. The primary outcome is reduction of comedones and inflammatory lesions measured by the YOLOv8 method plus microbiome restoration. That requires enrollment, laboratory analysis, and statistical comparison before reporting. Lesion counts alone are not enough here. Microbiome samples must be processed, checked, and compared across all four groups.
What acne-prone skin can do now
Acne develops when hair follicles clog from sebum, bacteria, and dead cells. That is why microbiome-directed probiotic and secretome approaches are being studied. Until this trial reports, proven care remains the practical path.
The 2024 American Academy of Dermatology guidance strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline, as reported in the 2024 dermatology guidance summary. Disease-targeted exosome and secretome products need FDA premarket review as drugs and biological products. The FDA issued its safety notice after serious adverse events linked to unapproved exosome products.
- Use a gentle cleanser, moisturizer, and sun protection daily
- Ask a clinician about benzoyl peroxide, a topical retinoid, or doxycycline
- Bring a full list of supplements, probiotics, and skin products
- Avoid unapproved exosome or secretome products sold for acne
You Might Also Like
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: A Source-Checked 2026 Briefing for People With Acne-Prone Skin
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: A Source-Checked 2026 Briefing for People With Acne-Prone Skin
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: A Source-Checked 2026 Briefing for People With Acne-Prone Skin